Tatsuki Mizuochi1, Katsuhiro Arai2, Takahiro Kudo3, Ryusuke Nambu4, Hitoshi Tajiri5, Tomoki Aomatsu6, Naoki Abe7, Toshihiko Kakiuchi8, Kunio Hashimoto9, Tsuyoshi Sogo10, Michiko Takahashi11, Yuri Etani12, Yugo Takaki13, Ken-Ichiro Konishi13, Jun Ishihara13, Hitoshi Obara14, Tatsuyuki Kakuma14, Shunsuke Kurei15, Yushiro Yamashita13, Keiichi Mitsuyama16. 1. Department of Pediatrics and Child Health, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 8300011, Japan. mizuochi_tatsuki@kurume-u.ac.jp. 2. Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan. 3. Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan. 4. Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan. 5. Department of Pediatrics, Osaka General Medical Center, Osaka, Japan. 6. Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan. 7. Department of Infection and Immunology, Aichi Children's Health and Medical Center, Obu, Aichi, Japan. 8. Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan. 9. Department of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 10. Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan. 11. Department of Pediatrics, Sapporo Kosei General Hospital, Sapporo, Japan. 12. Department of Gastroenterology and Endocrinology, Osaka Women's and Children's Hospital, Osaka, Japan. 13. Department of Pediatrics and Child Health, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 8300011, Japan. 14. Biostatistics Center, Kurume University School of Medicine, Kurume, Japan. 15. Medical & Biological Laboratories, Nagoya, Japan. 16. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Abstract
BACKGROUND: Various serologic markers such as anti-glycoprotein 2 antibodies and anti-Saccharomyces cerevisiae antibodies have been reported to be diagnostically useful in Crohn's disease. Mitsuyama et al. reported that antibodies to Crohn's disease peptide 353, a newly proposed serologic marker, were more useful in Japanese adults than anti-Saccharomyces. We addressed the same issue in Japanese children and adolescents. METHODS: Prospectively enrolled subjects under 17 years old assessed and treated at 12 pediatric centers in Japan included groups with Crohn's disease, ulcerative colitis, other intestinal diseases, or good health. The 3 serum markers were analyzed by enzyme-linked immunosorbent assays. RESULTS: Enrolled subjects, numbering 367, included 120 with Crohn's disease, 148 with ulcerative colitis, 56 with other intestinal diseases, and 43 healthy subjects. In Crohn's disease, anti-Crohn's disease peptide 353, anti-glycoprotein 2, and anti-Saccharomyces concentrations (median, 2.25, 3.0, and 8.9 U/mL) were significantly greater than in ulcerative colitis (1.1, 1.9, and 3.4; all P < 0.001), other intestinal diseases (1.1, 1.85, and 2.95; all P < 0.001), and healthy controls (1.1, 1.7, and 2.8; all P < 0.001), respectively. At 95% specificity, sensitivity of anti-Crohn's disease peptide (45.0%) was significantly higher than for anti-glycoprotein 2 (30.8%; P < 0.05) or anti-Saccharomyces (26.7%; P < 0.01). CONCLUSIONS: Anti-Crohn's disease peptide 353 proved more useful for diagnosis of Crohn's disease in Japanese children than the other 2 markers. To our knowledge, this is the first pediatric report to that effect.
BACKGROUND: Various serologic markers such as anti-glycoprotein 2 antibodies and anti-Saccharomyces cerevisiae antibodies have been reported to be diagnostically useful in Crohn's disease. Mitsuyama et al. reported that antibodies to Crohn's disease peptide 353, a newly proposed serologic marker, were more useful in Japanese adults than anti-Saccharomyces. We addressed the same issue in Japanese children and adolescents. METHODS: Prospectively enrolled subjects under 17 years old assessed and treated at 12 pediatric centers in Japan included groups with Crohn's disease, ulcerative colitis, other intestinal diseases, or good health. The 3 serum markers were analyzed by enzyme-linked immunosorbent assays. RESULTS: Enrolled subjects, numbering 367, included 120 with Crohn's disease, 148 with ulcerative colitis, 56 with other intestinal diseases, and 43 healthy subjects. In Crohn's disease, anti-Crohn's disease peptide 353, anti-glycoprotein 2, and anti-Saccharomyces concentrations (median, 2.25, 3.0, and 8.9 U/mL) were significantly greater than in ulcerative colitis (1.1, 1.9, and 3.4; all P < 0.001), other intestinal diseases (1.1, 1.85, and 2.95; all P < 0.001), and healthy controls (1.1, 1.7, and 2.8; all P < 0.001), respectively. At 95% specificity, sensitivity of anti-Crohn's disease peptide (45.0%) was significantly higher than for anti-glycoprotein 2 (30.8%; P < 0.05) or anti-Saccharomyces (26.7%; P < 0.01). CONCLUSIONS: Anti-Crohn's disease peptide 353 proved more useful for diagnosis of Crohn's disease in Japanese children than the other 2 markers. To our knowledge, this is the first pediatric report to that effect.
Authors: Shanthi V Sitaraman; Jan-Michael Klapproth; Daniel A Moore; Carol Landers; Stephan Targan; Ifor R Williams; Andrew T Gewirtz Journal: Am J Physiol Gastrointest Liver Physiol Date: 2004-09-23 Impact factor: 4.052
Authors: R K Russell; B Ip; M C Aldhous; M MacDougall; H E Drummond; I D R Arnott; P M Gillett; P McGrogan; L T Weaver; W M Bisset; G Mahdi; D C Wilson; J Satsangi Journal: J Pediatr Gastroenterol Nutr Date: 2009-02 Impact factor: 2.839
Authors: Arie Levine; Anne Griffiths; James Markowitz; David C Wilson; Dan Turner; Richard K Russell; John Fell; Frank M Ruemmele; Thomas Walters; Mary Sherlock; Marla Dubinsky; Jeffrey S Hyams Journal: Inflamm Bowel Dis Date: 2010-11-08 Impact factor: 5.325
Authors: Michael P Horn; Anna Maria Peter; Franziska Righini Grunder; Alexander B Leichtle; Johannes Spalinger; Susanne Schibli; Christiane Sokollik Journal: PLoS One Date: 2018-12-17 Impact factor: 3.240